Peter builds on more than 20 years of pharma and biotech expertise to drive corporate strategy and partnering efforts in his current role. Mammoth is a private company, co-founded by Nobel Laureate Jennifer Doudna, and focuses on next generation CRISPR systems translating into therapeutic and diagnostic applications. Peter joined the company from Casebia Therapeutics which he co-founded as a Joint Venture between Bayer and CRISPR Therapeutics, and which is now fully owned by CRISPR Tx. Prior to Casebia, Peter has been at Bayer Healthcare in various positions in the US and Germany covering commercial, business development and licensing, project management, operations, and R&D within various indication fields. Peter completed postdoctoral studies at Stanford University and holds a Ph.D. in Organic Chemistry from the University of Marburg. He is a co-inventor of more than 45 patents including for the approved drug Letermovir.
Jane Grogan, Graphite Bio